The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

doi:10.3389/fmolb.2022.870395

	The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
	Yuan, Meiqin 1,2; Wang, Zeng 1; Lv, Wangxia 1; Pan, Hongming 3
刊名	FRONTIERS IN MOLECULAR BIOSCIENCES
	2022-03-30
卷号	9
关键词	mCRC maintenance therapy EGFR monoclonal antibody panitumumab cetuximab
DOI	10.3389/fmolb.2022.870395
通讯作者	Pan, Hongming(panhongming@zju.edu.cn)
英文摘要	Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free survival (PFS) and overall survival (OS), and improve the overall response rate (ORR), which is the first-line treatment standard scheme for RAS wild-type mCRC currently. However, whether anti-EGFR mAb can be used for the maintenance treatment after the first-line treatment of mCRC remains controversial. We reviewed the recent studies on anti-EGFR mAb. The contents include five parts, introduction, anti-EGFR mAb in mCRC and its status in first-line therapy, establishment of the maintenance treatment pattern after the standard first-line treatment for mCRC, research progress of anti-EGFR mAb in mCRC maintenance therapy, and conclusion. More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients.
WOS关键词	METASTATIC COLORECTAL-CANCER ; FOLFIRI PLUS BEVACIZUMAB ; PHASE-III TRIAL ; WILD-TYPE KRAS ; 1ST-LINE TREATMENT ; OPEN-LABEL ; COMBINATION CHEMOTHERAPY ; NON-INFERIORITY ; CETUXIMAB ; OXALIPLATIN
WOS研究方向	Biochemistry & Molecular Biology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000784329900001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128603]
专题	中国科学院合肥物质科学研究院
通讯作者	Pan, Hongming
作者单位	1.Chinese Acad Sci, Univ Chinese Acad Sci, IBMC, Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Univ, Sch Med, Hangzhou, Peoples R China 3.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Yuan, Meiqin,Wang, Zeng,Lv, Wangxia,et al. The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy[J]. FRONTIERS IN MOLECULAR BIOSCIENCES,2022,9.
APA	Yuan, Meiqin,Wang, Zeng,Lv, Wangxia,&Pan, Hongming.(2022).The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy.FRONTIERS IN MOLECULAR BIOSCIENCES,9.
MLA	Yuan, Meiqin,et al."The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy".FRONTIERS IN MOLECULAR BIOSCIENCES 9(2022).